AAV Capsid TFRC Targeting for CNS-Wide Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for neurodevelopmental and neurological disorders face challenges in efficiently delivering genes throughout the central nervous system (CNS) due to the inability of engineered AAV capsids to effectively cross the blood-brain barrier and transduce primate brains with high efficiency.
Innovation Solution
Engineering AAV capsids to interact with the Transferrin Receptor (TFRC) by incorporating a targeting moiety, such as an n-mer motif, to enhance transduction of CNS tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If engineered AAV capsids are used for gene delivery, then gene transfer capability is achieved, but efficiency of crossing the blood-brain barrier and transducing CNS tissues remains insufficient
Solution Approach 1:
The patent modifies specific amino acid parameters of the AAV capsid protein structure, particularly in loop VIII (residues 588-589), to change the capsid's binding properties. By substituting specific residues (e.g., K588R, K588Q, K588E, K588D) or inserting n-mer motifs, the capsid's ability to interact with the transferrin receptor is enhanced, thereby improving CNS transduction efficiency and reliability simultaneously
Solution Approach 2:
The patent introduces the transferrin receptor as an intermediary target for AAV capsid binding. By engineering capsids to specifically bind to TFRC on the blood-brain barrier endothelial cells, the virus gains facilitated entry into the CNS through receptor-mediated transcytosis, significantly improving both delivery efficiency and transduction reliability
2Adaptability or versatility
If AAV capsids are engineered to cross the blood-brain barrier, then CNS delivery capability is improved, but species-specific differences reduce effectiveness in primates
Solution Approach 1:
The patent identifies and modifies specific amino acid parameters in the AAV capsid that are critical for species-specific recognition. By changing residues in loop VIII and introducing conserved n-mer motifs that bind to the transferrin receptor across species, the capsid achieves improved adaptability to primate CNS while maintaining high transduction productivity
Solution Approach 2:
The engineered AAV capsids acquire universal binding capability to the transferrin receptor across different species including primates. The modified capsid structure can now bind to TFRC on human and primate blood-brain barrier cells, enabling broad-spectrum CNS delivery capability while maintaining high transduction efficiency across species
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified AAV capsids demonstrate improved binding and transduction of CNS tissues, particularly in primate models, offering enhanced gene delivery efficiency and selectivity to CNS tissues.
Implementation Method 1
a targeting moiety effective to increase transduction of central nervous system tissues (CNS) via binding to a transferrin receptor (TFRC)
Data Source
AI summary
An engineered AAV capsid is provided, in which at least one protein on the capsid is modified to include a n-mer motif, which promotes transduction of the capsid into the central nervous system (CNS) through interaction with the Transferrin receptor. Further embodiments provide a vector system comprising one or more vectors encoding AAV capsids and a method of delivering cargo to the CNS. The method comprises administering, in vivo or in vitro, a AAV capsid according to embodiments described herein and the AVV capsid comprises one or more cargo molecules.